ReviewFrontiers in molecular neuroscience2024
Ototoxicity: a high risk to auditory function that needs to be monitored in drug development.
Review in Frontiers in molecular neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The cochlear morphometry compendium: High-resolution synchrotron measurements and normative reference values.Journal of anatomy · 2026Article
- Review
- Ototoxicity Associated with Antineoplastic Agents in the Pediatric Population: An Evidence-Based Review of Auditory Monitoring Strategies and Contemporary Diagnostic Frameworks-Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Cancer therapy-induced ototoxicity: Current challenges and emerging management strategies.Animal models and experimental medicine · 2026Review
- New Insight into Potential Otoprotective Effects of Lactoferrin: Is It Paradoxically Ototoxic? An Experimental Investigation.Audiology research · 2026Article
- Unraveling Endocannabinoid Signaling Pathways in Cisplatin-Induced Ototoxicity.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Computer models and artificial intelligence increase the fidelity and efficiency of the in vitro models for hearing loss.Biomedical engineering online · 2025Review
- Comparison of Distortion-Product Otoacoustic Emissions Measured in the Same Subjects Using Four Commercial Systems.Journal of clinical medicine · 2025Article
- Where are audiologists in the room of wizards? Oncology patient experiences with audiology in an Australian public hospital.Journal of cancer survivorship : research and practice · 2025Article
- Magnetic Cationic Liposomes-Based Delivery System Reduces Drug-Induced Cytotoxicity in an In Vitro Model of Hearing Loss.Nanomaterials (Basel, Switzerland) · 2025Article
- Hearing Impairment Among Drug-Resistant Tuberculosis Patients in Rural Eastern Cape: A Retrospective Analysis of Audiometric Findings.International journal of environmental research and public health · 2025Article
- Protective effects of MET channels on aminoglycosides- and cisplatin-induced ototoxicity.International journal of medical sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hearing loss constitutes a major global health concern impacting approximately 1.5 billion people worldwide. Its incidence is undergoing a substantial surge with some projecting that by 2050, a quarter of the global population will experience varying degrees of hearing deficiency. Environmental factors such as aging, exposure to loud noise, and the intake of ototoxic medications are implicated in the onset of acquired hearing loss. Ototoxicity resulting in inner ear damage is a leading cause of acquired hearing loss worldwide. This could be minimized or avoided by early testing of hearing functions in the preclinical phase of drug development. While the assessment of ototoxicity is well defined for drug candidates in the hearing field - required for drugs that are administered by the otic route and expected to reach the middle or inner ear during clinical use - ototoxicity testing is not required for all other therapeutic areas. Unfortunately, this has resulted in more than 200 ototoxic marketed medications. The aim of this publication is to raise awareness of drug-induced ototoxicity and to formulate some recommendations based on available guidelines and own experience. Ototoxicity testing programs should be adapted to the type of therapy, its indication (targeting the ear or part of other medications classes being potentially ototoxic), and the number of assets to test. For multiple molecules and/or multiple doses, screening options are available:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.